Sirona Biochem CEO’s Report on Progress
Momentum Public Relations
Press Release: September 21, 2017
VANCOUVER, BC–(Marketwired – September 21, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to provide a corporate update.
Dear Shareholders,
I would like to thank you for your continued support while we work through the negotiations for our skin lightener. The following is an update on our progress to date.
Skin Lightener, TFC-1067
We are pleased to announce that we have exchanged term sheets and advanced negotiations are ongoing with potential global partners. We will update our shareholders immediately upon any material change in the status of negotiations.
SGLT2 Inhibitor, SBM-TFC-039 (Wanbang)
Wanbang Biopharmaceuticals provided a progress report on the IND (Investigational New Drug) package that will go to the China Food and Drug Administration (CFDA). In vivo studies show that the SGLT2 Inhibitor significantly lowered blood glucose levels.
Further in vivo and in vitro studies, including toxicology, are wrapping up now and results are expected by November. CMC (chemistry, manufacturing and control) studies on pharmaceutical grade batch preparations are complete and have met reference standards for use in clinical studies.
Wanbang expects to file the IND to the CFDA by the end of this year. This will trigger another milestone payment of $500,000 USD to Sirona.
Recently, the Indian subsidiary of a global pharmaceutical company has expressed interest in licensing SBM-TFC-039 for India and have begun due diligence.
Cell Preservation and Anti-Aging (Glycoprotein) Library
In December 2016, we concluded testing of our glycoprotein compound library. Studies were successful in showing efficacy against various stressors in skin cells. There are many potential commercial applications of these compounds and interested partners requested a better understanding of the mechanism of action. We decided to go back to testing and do a full genomic study. These results will show us the pathways being affected within the cells and enable us to develop a more complete package of information for prospective companies. We are currently waiting for the report and anticipate receiving it early October 2017.
Acne Compound
Several of the compounds have completed chemistry and we will begin preclinical testing in Q4 2017. This was moved out slightly from mid-2017 due to chemistry process optimization.
Keloid Compound
We are working to put in place a Contract Research Organization (CRO) based in Europe with expertise in Keloid research to assist us. This has been delayed due to resource allocation.
Skin Lightener, TFC-849 (Valeant)
Our skin lightener asset, TFC-849, will be transferred with the sale of Obagi to Haitong International Zhonghua Finance Acquisition Fund I LP. The transaction is expected to be completed this year and we are continuing to work with Valeant during the transition. Limited partners of the fund include China Regenerative Medicine International Ltd. CRMI is a public company, traded on the Hong Kong stock exchange and currently focuses on three major business segments: tissue engineering, cell therapy, and cosmetics. With a China based company, they are well positioned to enter the skin lightening market.
Again, we thank you for your continued support and patience during this time.
Sincerely,
Dr. Howard Verrico, CEO
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem
Sirona Biochem Announces Resignation of Board Director
Momentum Public Relations
Press Release: September 13, 2017
VANCOUVER, BC–(Marketwired – September 13, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of Dr. Martin Gleave from the board of directors. Dr. Gleave is involved in a new venture that could result in a potential conflict. Accordingly both Dr. Gleave and the Company felt a resignation was most appropriate.
“We’d like to thank Dr. Gleave for his contribution to our company,” said Dr. Howard Verrico, CEO. “We wish him well in his future endeavors.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem, Technology
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Momentum Public Relations
Press Release: August 23, 2017
VANCOUVER, BC–(Marketwired – August 23, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces an extension to the term of 8,850,770 common share purchase warrants (the “Warrants”) originally issued on March 6, 2014. The warrants were issued as part of a private placement. The expiry dates will be extended as follows:
March 6, 2014 | |
Number of Warrants: | 8,850,770 |
Original Expiry Date of Warrants: | March 6, 2017 |
New Expiry Date of Warrants: | November 30, 2017 |
Exercise Price of Warrants: | $0.25 |
All other terms of the Warrants will remain unchanged.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem, Technology
The Fountain of Youth May Be Just Around the Corner In Vancouver
The Fountain of Youth May Be Just Around the Corner In Vancouver
Sirona Biochem makes safer and more effective cosmeceuticals
Vancouver-based Sirona Biochem is on track to crack the global market for skin lightening products, a market that has been predicted by Global Industry Analysts to hit US$23 billion by 2020. If that isn’t enough the company is also developing a product designed to forestall facial aging. Zion Market Research pegs the global anti-aging market at US$216.52 billion by 2021. The Company’s skin lightening products are far safer and far more effective than those which are currently on the market.
In hindsight it is not that surprising that Vancouver is becoming a hotbed of discovery when it comes to turning back the ravages of time. Botox as we know it today for the cosmetics industry, after all, was popularized in Vancouver by the husband and wife team of ophthalmologist Jean Carruthers and dermatologist Alistair Carruthers. They discovered that a toxin named botox helped eradicate the lines and wrinkles caused by aging.
Sirona Biochem Corp. (TSX-V:SBM) is a discovery and development stage biochem company that has developed a proprietary way to treat carbohydrate molecules using fluorination chemistry. This process prevents molecules from breaking down when exposed to enzymes. This now opens the door to developing a new field of therapeutics.
The company also has an anti-aging product based on synthesizing the glycoprotein found in the blood serum of Antarctic water fish and is currently in the testing and validation stage. The glycoprotein helps preserve the fish and its cells from the freezing water. When applied to humans, it helps prevent skin cells from dying, and also protects them from the harsh glare of ultra-violet radiation.
The good news for Sirona, however, doesn’t stop there. The company believes their stabilized carbohydrate molecules have applications in the treatment of cancer, pain, diabetes and inflammation. Sirona has developed an SGLT2 inhibitor as a Type 2 Diabetes treatment. Research and consulting firm Global Data has predicted that the global type 2 diabetes market will almost double from US$31.2 billion in 2015 to US58.7 billion by 2025.
SGLT2 inhibitors are a recent development in the fight against Type 2 diabetes. Most traditional diabetes treatments work by controlling insulin production or regulating blood sugar levels. SGLT2 inhibitors work by acting in the kidneys to reduce the reabsorption of glucose into the bloodstream.
Sirona’s strategy is to do the basic discovery and development work on a given product, and then to license the technique or joint venture it for commercialization, marketing and distribution. In 2014 the company signed a licensing agreement with Wanbang Biopharmaceuticals for the Chinese market. Wanbang will develop and commercialize Sirona’s SGLT2 inhibitor exclusively in the People’s Republic of China. The company also has a licensing agreement with Obagi Medical Products for a skin lightening agent.
Sirona Biochem was founded in 2009 by CEO Dr. Howard Verrico. The first thing Verrico did was to acquire the exclusive global license from TFChem for its proprietary SGLT2 Inhibitor. TFChem is based in Rouen, France. Verrico thought enough of TFChem’s research that he then went on to acquire TFChem as a wholly-owned subsidiary from its founder Dr. Geraldine Deliencourt-Godefroy. She then became Sirona’s Chief Science Officer and largest shareholder. TFChem now acts as Sirona’s research and development laboratory. A respected scientist, Deliencourt-Godefroy has also received a variety of honours in France including the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.
The company sees the cosmetic and cosmeceutical industry as its first major market penetration target for two important reasons. The first is that, as noted above, the financial reward for creating a fountain of youth will be immense. Secondly, the amount of regulatory testing for cosmetics is miniscule when compared to that involved in the pharmaceutical industry. The company intends to use the cash flow created by its anti-aging platform and skin colour lightening products, to finance the creation of more traditionally flavoured therapies for things like cell preservation and anti-inflammatories.
The company’s development focus is based on three high-return fields of discovery and development:
- Therapeutics: diabetes, anti-inflammatories and anti-infectives
- Cosmeceuticals: anti-aging and depigmenting agents
- Biological Ingredients: inducers and adjuvants for biological development and preservation.
With an SLGT2 inhibitor in the pre-clinical stage and four cosmetic products in the testing and validation phase, the company has received revenues and will continue to do so in the future from Wanbang for its SLGT2 inhibitor. Sirona also receives revenue from Obagi Medical products for a skin lightener, one of three skin lightening agents under development. It is also working on an acne treatment, an anti-inflammatory and an anti-infective.
Much of Sirona’s work is ground-breaking. Stabilizing carbohydrate molecules opens up new fields for therapeutic interventions and may rejuvenate older treatments which became stalled. Synthesizing the glycoprotein found in the blood serum of Antarctic fish may produce a product that slows down the aging of skin. One way to illustrate its potential value is that when TFChem first synthesized the glycoprotein, cosmetic giant L’Oreal Group, the world’s largest cosmetics company slapped a field-of-use patent on it. As it turns out the first synthesis was not stable, but the later ones were, and L’Oreal was out of luck.
While Sirona is concentrating on developing cosmetic products, it hasn’t neglected the medical side of things. The company has a pipeline of products that are heading towards the market. The anti-aging compound is now in the testing and validation phase.
The company has a 52-week high of $0.20 and a 52-week low of $0.12. As of June 16, 2017, it was trading at $0.17. And if you were wondering, Sirona is the name of the Celtic goddess of healing.
- Published in Bio technology, Blog, Sirona Biochem, Technology
Sirona Biochem Closes Convertible Note Financing
Sirona Biochem Closes Convertible Note Financing
Momentum Public Relations
Press Release: June 5, 2017
VANCOUVER, BC–(Marketwired – June 05, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) is pleased to announce that it has closed the non-brokered private placement (the “Private Placement”) of convertible notes (“Notes”). The financing was oversubscribed, resulting in gross proceeds of $587,000. Each Note is convertible at the option of the holder into one common share of the company at a conversion price of $0.18 per share.
The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period.
All securities issued in connection with the private placement will be subject to a statutory hold period expiring on October 5, 2017.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem, Technology
Sirona Biochem Announces Convertible Note Financing
Sirona Biochem Announces Convertible Note Financing
Momentum Public Relations
Press Release: May 31, 2017
VANCOUVER, BC–(Marketwired – May 31, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) announced today a non-brokered private placement (the “Private Placement”) of convertible notes (“Notes”) for gross proceeds of up to $500,000. Each Note will be convertible at the option of the holder into one common share of the company at a conversion price of $0.18 per share during the 18 month term of the Notes.
The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period. The Notes are unsecured and transferable, subject to resale restrictions under applicable securities laws and TSX Venture Exchange requirements.
All securities issued in connection with the private placement will be subject to a statutory hold period of four months commencing from the date of issuance of the Notes. Closing of the private placement is subject to customary conditions, including TSX Venture Exchange acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem, Technology
IWS Announces Management Change
IWS Announces Management Change
VANCOUVER, BRITISH COLUMBIA–(Marketwired – May 8, 2017) – International Wastewater Systems Inc. (“IWS” or the “Company”) (CSE:IWS)(CSE:IWS.CN)(CNSX:IWS)(FRANKFURT:IWI)(OTC PINK:INTWF) announces that Yaron Conforti will be leaving his role as the Company’s Chief Financial Officer and a member of its Board of Directors, to pursue new opportunities.
Mr. Conforti will remain a consultant to IWS to assist with the transition to the newly appointed CFO, Mr. David Alexander, CA, CPA. Mr. Alexander has extensive experience as a CFO and his past achievements include CFO of Arakis Energy Corporation (subsequently sold to Talisman Energy TSX:TLM), and Nortran Pharmaceuticals, Inc., (later Cardiome Pharma NASDAQ:CRME).
Lynn Mueller, Chairman and CEO of IWS commented: “Yaron Conforti provided valuable leadership as our CFO and a member of our Board of Directors since 2015. I would like to thank him for his contributions and wish him every success in the future. We welcome David Alexander, an experienced CFO who further strengthens our management team during a period of significant growth for IWS.”
ON BEHALF OF THE BOARD
Lynn Mueller, Chairman and Chief Executive Officer
About International Wastewater Systems Inc.
International Wastewater Systems Inc. is a world leader in thermal heat recovery. IWS systems recycle thermal energy from wastewater, generating the most energy efficient and economical systems for heating, cooling & hot water for commercial, residential and industrial buildings. IWS is publicly traded in Canada (CSE:IWS)(CSE:IWS.CN)(CNSX:IWS), the United States (OTC PINK:INTWF) and Germany (FRANKFURT:IWI).
CONTACT INFORMATION
-
International Wastewater Systems Inc.
Lynn Mueller
CEO
(604) 475-7710
- Published in Bio technology, Energy, Green Technology, International Wastewater Systems, News Home, Technology
Biggest U.S. Companies Setting More Renewable-Energy Targets
Biggest U.S. Companies Setting More Renewable-Energy Targets
-
Corporations bought 2.5 gigawatts of clean energy last year
-
Fortune 500 companies saving $3.7 billion with clean power
Almost half of the biggest U.S. companies have established clean-energy targets for themselves, according to a report Tuesday from sustainable investors and environmental groups including the World Wildlife Fund.
It’s not just the biggest U.S. companies — 44 percent of the smallest 100 members of the Fortune 500 have also set goals, up from 25 percent in 2014, and 48 percent of the entire list.
Many are finding that renewable energy isn’t just cleaner, it’s also often cheaper. About 190 Fortune 500 companies collectively reported about $3.7 billion in annual savings, according to Power Forward 3.0, a report by WWF, Ceres, Calvert Research & Management and CDP.
“We’re not talking about anecdotal information anymore,” Marty Spitzer, a WWF senior director of climate and renewable energy in Washington, said in an interview. “We’re talking about large, large savings.”
Potential savings and sustainability goals prompted corporations to buy almost 3.7 gigawatts of power generated by clean-energy projects in 2015, and another 2.5 gigawatts last year, almost all from wind and solar, according to Bloomberg New Energy Finance.
But it’s no longer just tech companies. About 63 percent of Fortune 100 companies have clean-energy targets, according to the report. Such targets include commitments to reduce greenhouse-gas emissions and increase energy efficiency and renewable energy.
The 190 Fortune 500 companies reported emission reductions equivalent to mothballing 45 coal-fired power plants for a year, according to the report. It also found that 23 of Fortune 500 companies have 100 percent renewable-energy targets.
By Brian Eckhouse
- Published in Bio technology, Blog, Energy, Green Technology, International Wastewater Systems, News Home, Technology
Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis
Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec
Momentum Public Relations
Press Release: April 19, 2017
Tetra Bio-Pharma Inc. (“Tetra”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) and Aphria Inc. (“Aphria”) (TSX:APH) (OTCQB:APHQF), announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001. The formulation and packaging will be completed by Tetra, under its CDSA dealer’s licence, at its New Brunswick facility. Based on the success of the venture, Tetra and Aphria may expand into other provinces. The venture is preparing to initiate its commercial operations early summer 2017 with revenues commencing in Tetra’s third quarter of 2017 and Aphria’s first quarter of 2018.
“This commercial venture is an important decision for Tetra shareholders as it will start generating revenues this summer which will be invested back into developing PPP001 as a prescription pharmaceutical,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will be accelerating its manufacturing and quality studies as required by the U.S. and Canadian prescription drug and controlled substance regulations. The investment in this research will be offset by sales revenues generated under the ACMPR.”
“The commercial venture between Tetra and Aphria will enhance Aphria’s brand visibility and distribution of our high-quality medical grade cannabis into the maritime provinces and Quebec, as we look to meet the commercial demand for PPP001,” said Vic Neufeld, CEO of Aphria Inc. “As a leading Canadian licensed producer, it was important for us to work with an organization that shares our focus on pharmaceutical-grade quality assurance and control. Tetra’s emphasis on developing products driven by patient needs and scientific research and development makes them the perfect partner in this important next step for Aphria.”
Tetra and Aphria have invested in the development of its PPP001 drug and will continue to invest to bring PPP001 to market in both Canada and USA as the first prescription drug using dried cannabis. The corporations have developed a high quality dried cannabis product and would like to make it available to physicians under the current ACMPR program. The quality and clinical research studies completed to date would be integrated into a joint Continuing Medical Education program for physicians and pharmacists. Tetra and Aphria have concluded that there is demand for an evidence-based approach in medical cannabis and the two companies intend on using their pharmaceutical approach to help patients. The venture will also be commercializing devices for the inhalation of medical cannabis.
About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
About Aphria:
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
- Published in Bio technology, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
International Wastewater Systems closes $725,100 last financing tranche
International Wastewater Systems closes $725,100 last financing tranche
Momentum Public Relations
Press Release: April 07, 2017
International Wastewater Systems Inc., further to its news release dated Feb. 27, 2017, has closed the final tranche of the company’s brokered private placement, led by Haywood Securities Inc. as agent.
Under the final tranche of the brokered placement, the company has issued 2,417,000 units at a price of 30 cents per unit for gross proceeds of $725,100. Each unit consists of one common share and one common share purchase warrant of the company. Each warrant entitles the holder to purchase one share until Feb. 27, 2019, at an exercise price of 40 cents per share.
The company has paid cash commissions in the amount of $31,282.50 from the sale of units under the final tranche of the brokered placement. The company has also issued to the agent and members of the selling group an aggregate of 104,275 non-transferable warrants. Each agent’s warrant entitles the holder to purchase one share at a price of 30 cents until Feb. 27, 2019.
As previously announced on Jan. 19, 2017, the company amended the terms of the company’s non-brokered private placement completed on Dec. 23, 2016, to offer each participant in the non-brokered placement one warrant for each share purchased in the non-brokered placement on the same terms as the brokered placement. Accordingly, the company has issued a total of 2,275,333 warrants to purchasers from the non-brokered placement.
In total, the company raised aggregate gross proceeds of $2,205,655 pursuant to the non-brokered placement and the brokered placement.
All securities distributed pursuant to the brokered placement and non-brokered placement are subject to a statutory hold period of four months and a day from the date of issuance.
About International Wastewater Systems Inc.
International Wastewater Systems is a world leader in thermal heat recovery. International Wastewater’s systems recycle thermal energy from waste water, generating the most energy-efficient and economical systems for heating, cooling and hot water for commercial, residential and industrial buildings.
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Bio technology, Energy, Green Technology, International Wastewater Systems, News Home, Technology